Clinical Correlates of Vascular Parkinsonism
Arch Neurol 56:98-102, Winikates,J.&Jancovic,J., 1999
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Idiopathic Hyposmia As a Preclinical Sign of Parkinson's Disease
Ann Neurol 56:173-181,169, Ponsen,M.M.,et al, 2004
Subclinical Dopaminergic Dysfunction in Asymptomatic Parkinson's Disease Patients' Relatives with a Decreased Sense of Smell
Ann Neurol 50:34-41, Berendse,H.W.,et al, 2001
Syndrome of Normal Pressure Hydrocephalus:Possible Relation to Hypertensive & Arteriosclerotic Vasculopathy
JNNP 40:73-79, Koto,A.,et al, 1977
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Exploring the Association Between Rosacea and Parkinson Disease
JAMA Neurol 73:529-534, Egeberg, A.,et al, 2016
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Role of Brain Imaging in Early Parkinsonism
BMJ 324:d638, Breen,D.P.,et al, 2011
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Increased Risk of Parkinsonism in Women Who Underwent Oophorectomy Before Menopause
Neurol 70:200-209, Rocca,W.A.,et al, 2008
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Functional Imaging in Parkinson Disease
Neurol 70:1478-1488, Nandhagopal,R.,et al, 2008
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Attempted and Completed Suicides After Subthalamic Nucleus Stimulation for Parkinsons Disease
JNNP 79:952-954, Soulas,T.,et al., 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Gender Differences in Parkinsons Disease
JNNP 78:819-824,787, Haaxma,C.A.,et al, 2007
Gout and Risk of Parkinson Disease: A Prospective Study
Neurol 69:1696-1700, Alonso,A.,et al, 2007
Parkinson Disease, 10 Years After Its Genetic Revolution: Multiple Clues to a Complex Disorder
Neurol 69:2093-2104, Klein,C. &Schlossmacher,M.G., 2007
Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006
Collaborative Analysis of a-Synuclein Gene Promotor Variability and Parkinson Disease
JAMA 296:661-670, Maraganore,D.M.,et al, 2006
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
The role of radiotracer imaging in Parkinson disease
Neurol 64:208-215, Ravina, B., et al, 2005
[99mTc]TRODAT-1 SPECT Imaging Correlates with Odor Identification in Early Parkinson Disease
Neurol 64:1716-1720, Siderowf,A.,et al, 2005
Occupation and Parkinsonism in Three Movement Disorders Clinics
Neurol 65:1430-1435, Goldman,S.M.,et al, 2005
Excessive Daytime Sleepiness and Subsequent Development of Parkinson Disease
Neurol 65:1442-1446, Abbott,R.D.,et al, 2005
Neuroprotection in Parkinson Disease, Mysteries, Myths, and Misconceptions
JAMA 291:358-364, Schapira,A.H.V.&Olanow,C.W., 2004
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol 60:1059-1064,1043, Chen,H.,et al, 2003
Incidence and Prediction of Falls in Parkinson's Disease: A Prospecitve Multidisciplinary Study
JNNP 72:721-725, Wood,B.H.,et al, 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Intakes of Vitamins E and C, Carotenoids, Vitamin Supplements, and PD Risk
Neurol 59:1161-1169, Zhang,S.M.,et al, 2002
Welding-Related Parkinsonism
Neurol 56:8-13,4, Racette,B.A.,et al, 2001
Functional Correlates of Pallidal Stimulation for Parkinson's Disease
Ann Neurol 49:155-164,142, Fukuda,M.,et al, 2001
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
NEJM 344:710-719,763, Freed,C.R.,et al, 2001
[123I]Beta-CIT SPECT Imaging Assessment of the Rate of Parkinson's Disease Progression
Neurol 57:2089-2094, Marek,K.,et al, 2001
Striatal Dopamine Trnasporter Binding Assessed by [I-123]IPT and Single Photon Emission Computed tomography in Patients with Early Parkinson's Disease, Implications for a Preclinical Diagnosis
Arch Neurol 57:205-208, Schwarz,J.,et al, 2000
Susceptibility to Neuroleptic Malignant Syndrome in Parkinson's Disease
Neurol 52:777-781, Ueda,M.,et al, 1999
Long-Term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease
Arch Neurol 56:179-187, Hauser,R.A.,et al, 1999